Heal2gether Overview
For people with diabetes, even a small sore can be a big problem. If left untreated, foot sores may lead to serious complications.
As the manufacturer of Dermagraft®, Advanced BioHealing is dedicated to raising awareness about diabetic foot sores and aims to help the thousands of people across the nation who are at risk of developing the condition.
Heal2gether is a community health education program created by Advanced BioHealing to use education and action to foster awareness about diabetic foot ulcers—what they are, why they need to take special care of their feet, how to identify early warning signs, and the importance of seeking treatment from a wound care specialist immediately.
In addition, the Heal2gether Partnership Program features a phone support program, which is a free service that pairs patients with a personal treatment partner who will help them through every step of the healing process with Dermagraft.
We invite you to explore Heal2gether.org to learn more.
Important Safety Information about Dermagraft®
Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than 6 weeks duration, which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. Refer to Dermagraft Directions for Use for more information. Results may vary and not all patients will achieve complete wound closure with Dermagraft. In the pivotal trial, a 64% relative increase in complete wound closure was seen in the Dermagraft-treated patients; 30.0% of Dermagraft and 18.3% of conventional therapy patients achieved complete wound closure at 12 weeks. The most frequently reported adverse events experienced by patients in the Dermagraft group (terms ≥ 5%) included infection, accidental injury, skin dysfunction/blister, flu syndrome, osteomyelitis, surgeries involving study ulcer, wound enlargement/skin ulcer, cellulitis and peripheral edema/localized swelling. These adverse events were similar to those seen in the control group.